Genipin inhibits RANKL-induced osteoclast differentiation through proteasome-mediated degradation of c-Fos protein and suppression of NF-κB activation

Journal of Pharmacological Sciences

Volumn 124, Issue 3, 2014, Pages 344-353

  Lee, Chang Hoon ^a   Kwak, Sung Chul ^a   Kim, Ju Young ^a   Oh, Hyun Mee ^b   Rho, Mun Chual ^b   Yoon, Kwon Ha ^a   Yoo, Wan Hee ^c   Lee, Myeung Su ^a   Oh, Jaemin ^a  

^a Wonkwang University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

Author keywords

c Fos; Differentiation; Genipin; NFATc1; Osteoclast

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BIOLOGICAL MARKER; CELL PROTEIN; GENIPIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NFATC1 PROTEIN; OSCAR PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEASOME; PROTEIN C FOS; TRAP PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; IN VITRO STUDY; INTRACELLULAR SIGNALING; MACROPHAGE CULTURE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GARDENIA; IRIDOIDS; MALE; MICE; MICE, INBRED ICR; MOLECULAR TARGETED THERAPY; NF-KAPPA B; OSTEOCLASTS; OSTEOPOROSIS; PHYTOTHERAPY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND;

EID: 84897388430     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13174FP     Document Type: Article

References (29)

1. Hämäläinen H, Kaarela K, Kröger H, Kauppi M, Järvenpää S, Hakala M, et al. Changes in bone mineral density in premenopausal women with rheumatoid arthritis during a two-year follow-up. Joint Bone Spine. 2007;74:482-487. (Pubitemid 47588967)
2. Madsen H, Brixen K, Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease - a population-based database study. Clin Respir J. 2010;4:22-29.
3. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345-357. (Pubitemid 30649812)
4. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342. (Pubitemid 40852708)
5. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007;40:251-264. (Pubitemid 46054562)
6. Green JR, Clézardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol. 2002;25:S3-S9. (Pubitemid 35453651)
7. Lin YH, Tsai SC, Lai CH, Lee CH, He ZS, Tseng GC. Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials. 2013;34:4466-4479.
8. Kim ES, Jeong CS, Moon A. Genipin, a constituent of Gardenia jasminoides Ellis, induces apoptosis and inhibits invasion in MDA-MB-231 breast cancer cells. Oncol Rep. 2012;27:567-572.
9. Wang QS, Xiang Y, Cui YL, Lin KM, Zhang XF. Dietary blue pigments derived from genipin, attenuate inflammation by inhibiting LPS-induced iNOS and COX-2 expression via the NF-κB inactivation. PLoS One. 2012;7:e34122.
10. Koo HJ, Lim KH, Jung HJ, Park EH. Anti-inflammatory evaluation of gardenia extract, geniposide and genipin. J Ethnopharmacol. 2006;103:496-500.
11. Frohbergh ME, Katsman A, Botta GP, Lazarovici P, Schauer CL, Wegst UG, et al. Electrospun hydroxyapatite-containing chitosan nanofibers crosslinked with genipin for bone tissue engineering. Biomaterials. 2012;33:9167-9178.
12. Park JE, Lee JY, Kim HG, Hahn TR, Paik YS. Isolation and characterization of water-soluble intermediates of blue pigments transformed from geniposide of Gardenia jasminoides. J Agric Food Chem. 2002;23;50:6511-6514.
13. Chang Y, Hsu CK, Wei HJ, Chen SC, Liang HC, Lai PH, et al. Cell-free xenogenic vascular grafts fixed with glutaraldehyde or genipin: in vitro and in vivo studies. J Biotechnol. 2005;120:207-219. (Pubitemid 41429281)
14. Liu Z, Zhou Q, Zhu J, Xiao J, Wan P, Zhou C, et al. Using genipin-crosslinked acellular porcine corneal stroma for cosmetic corneal lens implants. Biomaterials. 2012;33:7336-7346.
15. Song F, Zhang LM, Yang C, Yan L. Genipin-crosslinked casein hydrogels for controlled drug delivery. Int J Pharm. 2009;373:41-47.
16. Koo HJ, Song YS, Kim HJ, Lee YH, Hong SM, Kim SJ, et al. Antiinflammatory effects of genipin, an active principle of gardenia. Eur J Pharmacol. 2004;495:201-208. (Pubitemid 38891877)
17. Li CC, Hsiang CY, Lo HY, Pai FT, Wu SL, Ho TY. Genipin inhibits lipopolysaccharide-induced acute systemic inflammation in mice as evidenced by nuclear factor-κB bioluminescent imaging-guided transcriptomic analysis. Food Chem Toxicol. 2012;50:2978-2986.
18. Lee ZH, Kim HH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun. 2003;305:211-214. (Pubitemid 36555454)
19. Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med. 1997;3:1285-1289. (Pubitemid 27508833)
20. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195-2224.
21. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007;282:18245-18253. (Pubitemid 47100255)
22. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292-304. (Pubitemid 46480961)
23. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med. 2005;83:170-179. (Pubitemid 40487405)
24. Wang ZQ, Ovitt C, Grigoriadis AE, Möhle-Steinlein U, Rüther U, Wagner EF. Bone and haematopoietic defects in mice lacking c-fos. Nature.1992;360:741-745. (Pubitemid 23012271)
25. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 1994;266:443-448.
26. Stancovski I, Gonen H, Orian A, Schwartz AL, Ciechanover A. Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes. Mol Cell Biol. 1995;15:7106-7116.
27. Ito Y, Inoue D, Kido S, Matsumoto T. c-Fos degradation by the ubiquitin-proteasome proteolytic pathway in osteoclast progenitors. Bone. 2005;37:842-849. (Pubitemid 41773495)
28. Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, et al. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatology. 2004;39:167-178. (Pubitemid 38461479)
29. Hiramatsu K, Sakata H, Horita Y, Orita N, Kida A, Mizukami A, et al. Mesenteric phlebosclerosis associated with long-term oral intake of geniposide, an ingredient of herbal medicine. Aliment Pharmacol Ther. 2012;36:575-586.